No headlines found.
OraSure to Launch OraQuick HIV Self-Test in Canada
Globe Newswire (Tue, 10-Feb 8:05 AM ET)
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
Globe Newswire (Mon, 9-Feb 4:15 PM ET)
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
Globe Newswire (Thu, 15-Jan 1:00 PM ET)
Business Wire (Thu, 15-Jan 8:30 AM ET)
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee Urine Collection Device for FDA Review
Globe Newswire (Mon, 5-Jan 8:00 AM ET)
Globe Newswire (Wed, 17-Dec 1:23 PM ET)
Business Wire (Wed, 17-Dec 8:00 AM ET)
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
Orasure Technologies trades on the NASDAQ stock market under the symbol OSUR.
As of February 20, 2026, OSUR stock price declined to $2.76 with 109,777 million shares trading.
OSUR has a beta of 0.64, meaning it tends to be less sensitive to market movements. OSUR has a correlation of 0.07 to the broad based SPY ETF.
OSUR has a market cap of $197.98 million. This is considered a Micro Cap stock.
Last quarter Orasure Technologies reported $27 million in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.04.
In the last 3 years, OSUR traded as high as $8.45 and as low as $2.08.
The top ETF exchange traded funds that OSUR belongs to (by Net Assets): VTI, IWM, VXF, IWN, SCHA.
OSUR has underperformed the market in the last year with a price return of -29.9% while the SPY ETF gained +13.6%. However, in the short term, OSUR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +26.0% vs +4.3% return in SPY. But in the last 2 weeks, OSUR shares have been beat by the market, returning +1.1% compared to an SPY return of +1.7%.
OSUR support price is $2.73 and resistance is $2.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OSUR shares will trade within this expected range on the day.